Disease	Diagnostic	Prognostic	Therapeutic
Brugada syndrome	+	+	+

Recommendation	Consensus statement instruction	Ref.
Genetic testing with sequencing of SCN5A is recommended for an index case diagnosed with BrS with a type I ECG in standard or high precordial leads occurring either (i) spontaneously, or (ii) induced by sodium‐channel blockade in presence of supporting clinical features or family history.		21 , 171
Rare variants in genes with a disputed or refuted gene‐disease clinical validity should not be reported routinelya for BrS genetic testing in a diagnostic setting.		21
Targeted sequencing of variant(s) of unknown significance in SCN5A with a population allele frequency <1 × 10−5 identified in an index case can be considered concurrently with phenotyping for family members, following genetic counselling, to assess variant pathogenicity through co‐segregation analysis.		172
Variant‐specific genetic testing is recommended for family members and appropriate relatives following the identification of the disease‐causative variant.		Expert opinion
Predictive genetic testing (of pathogenic SCN5A variants) in related children is recommended from birth onward (any age).		Expert opinion